Interesting take: "...On the Up-side; both primary drug candidates get approved in 2010 and the stock soars back to its high. On the downside; neither drug gets approved and the shares plummet. Now is the time when management at XNPT needs to really ‘communicate’ with its shareholders. Some weekly postings from the CEO and CFO on its web site could do no harm: ‘This is where we’re at’. This is where confidence, trust and a little reassurance go a long, long way..."
I am serious, you mail or phone the company and ask them to inform us.
At least they already have had the meeting with GSK people .... and it must be that GSK is going further with XNPT , that is why we saw a good buy volume the last three days...and yesterday it went from 8.77 to 8.5 on no ore then 100.000 shares.
But they must first have the meeting with the FDA people before they can annonce their new strategy. So they are a bit lazy over there and they will wait to communicate with you guys ..or they wait so that they can buy more cheap shares for themselves (through their family members so that we never can know about that)
Anyway, it looks good this far